AIC284 is an IL-2 mutein, especially engineered to maintain the activating effect of wildtype IL-2 on Treg cells and, at the same time, reduce the toxicity associated with systemic responses. In vivo models of Type-I Diabetes, Systemic lupus erythematosus and Multiple sclerosis have proven AIC284 to be efficacious and safe. Given its unique profile, AIC284 has the potential to become the gold-standard treatment for all autoimmune diseases with underlying Treg cell deficiency.
AIC284 is open for sale of all relevant assets, including clinical grade drug product and a robust set of patents conferring broad global compound and formulation protection in the context of autoimmunity.
Interested in learning more about this unique approach against autoimmunity? Please contact: business(at)aicuris.com
If you have further questions regarding partnering of our projects please contact: